Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.

Abstract

The suggested phase II dose on a continuous 42-day dosing schedule is 1,331 mg/m2/d. Linear pharmacologic parameters of the parent compound and metabolites are demonstrated.